Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Manage your formulary budget
Find generic entry opportunities
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Hydrogel-forming sustained-release preparation|
|Abstract:||The invention provides a hydrogen-type sustained-release preparation comprising (1) at least one drug, (2) an additive which insures a penetration of water into the core of the preparation and (3) a hydrogen-forming polymer, wherein said preparation is capable of undergoing substantially complete gelation during its stay in the upper digestive tract such as stomach and small intestine and is capable of releasing the drug in the lower digestive tract including colon. By the preparation of the invention, the drug is efficiently released and absorbed even in the colon so that a steady and sustained release effect can be achieved.|
|Inventor(s):||Sako; Kazuhiro (Shizuoka, JP), Nakashima; Hiroshi (Shizuoka, JP), Sawada; Toyohiro (Shizuoka, JP), Okada; Akira (Shizuoka, JP), Fukui; Muneo (Shizuoka, JP)|
|Assignee:||Yamanuchi Pharmaceutical Co., Ltd. (Tokyo, JP)|
Patent Claim Types:|
see list of patent claims
Back Citations: 28th percentile
Forward Citations: 1st percentile
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||219933||<disabled in preview>|
|Australia||682827||<disabled in preview>|
|Australia||4983893||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.